DOCSLIB.ORG

Suramin As a Chemo- and Radio-Sensitizer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Suramin As a Chemo- and Radio-Sensitizer SURAMIN AS A CHEMO- AND RADIO-SENSITIZER: PRECLINICAL TRANSLATIONAL STUDIES DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Yan Xin, M.S. ***** The Ohio State University 2006 Dissertation Committee: Dr. M. Guillaume Wientjes, Adviser Approved by Dr. Jessie L.-S. Au ____________________________________ Adviser Dr. Duxin Sun Graduate Program in Pharmacy ABSTRACT Previous studies in our laboratory showed that low-dose suramin, an inhibitor of fibroblast growth factor action, enhances sensitivity of various human tumors in preclinical and clinical studies to chemotherapy. Chemosensitization required apoptosis, and increased the extent and duration of the induction of apoptosis. The primary focus of this dissertation research was to explore, in preclinical studies, therapeutic approaches for therapy enhancement based on this mechanism. A phase III clinical trial in superficial bladder cancer, which emanated from our laboratory, showed that optimizing mitomycin C delivery nearly doubled the recurrence- free survival of treated patients to 40%. Tumor sensitization with suramin might yield further therapeutic improvements, and was investigated in in vitro and in vivo studies. Studies in Chapter 2 demonstrated enhanced antitumor activity of mitomycin C, administered at subtherapeutic and therapeutic regimens. Various preclinical and clinical studies determined that suramin sensitized tumor tissue at low but not at high concentrations, presumably due to additional pharmacologic effects at elevated concentrations. Studies to overcome this limitation, especially in tumors containing high fibroblast growth factor concentrations, used pentosan polysulfate, another nonspecific FGF inhibitor. This agent was also a chemosensitizer, but combined use with suramin did not increase the overall efficacy (Chapter 3). ii Radiotherapy depends on induction of apoptosis for its anticancer effect, as is the case for many forms of chemotherapy, and led to our evaluation of suramin as radiosensitizer. Results in Chapter 4 and Chapter 5 showed that low-dose suramin sensitized the radiation response of both radiosensitive (prostate PC-3) and relatively radioresistant (pharynx FaDu, pancreatic Hs 766T) xenograft tumors, thereby further extending the clinical application of suramin to modulate radiotherapy. More importantly, the radiosensitizaiton effect of suramin had tumor type specific dose dependence, with a narrow sensitiziting window in FaDu and a wider range in Hs 766T (pancreatic) xenograft tumors (Chapter 5), suggesting the necessity of drug target-specified dosing regimen for suramin. To better understand the biphasic effect of suramin in combination with radiation, pharamacodynamic studies at a microscopic level were conducted (Chapter 6). The results indicated that low-dose but not high-dose suramin enhanced radiation-induced apoptosis, inhibiting radiation-induced upregulation of phospho-ERK and survivin, two survival signals involved in radioresistance. iii DEDICATION Dedicated to my dear parents, my brothers, sisters-in-law, and nephews iv ACKNOWLEDGMENT I wish to express my sincere appreciation to my advisor, Dr. M. Guillaume Wientjes, who has made this dissertation come true. His scientific enthusiasm, integrity and dedication have been inspiring me throughout my graduate study. His patience and encouragement helped me through the frustrated moments. He is a great mentor and friend. My deep appreciation also goes to Dr. Jessie L-S. Au, for all her invaluable contribution to my overall scientific training and growth, as well as her kind friendship in daily life. Being a successful scientist, a wife, and a mother, she is definitely an amazing role model for me. Special thanks go to Dr. Yong Wei for his invaluable scientific suggestions, discussions, and input into my thesis work. His enthusiasm and dedication to science have greatly inspired me. I appreciate his encouragement and friendship. A special recognition is extended to our collaborators, Dr. John C. Grecula and Dr. Nilendu Gupta, in the College of Medicine and Public Health. It is their dedication that made our cooperation productive. Everyone in the lab has played a special role in my training. I feel really grateful to have such an enjoyable environment to finish the most important training in my career. I want to thank each of them for the sweet memorable days. In particular, my sincere v gratitude goes to Dr. Yuebo Gan and Dr. SaeHeum Song, who walked me through the starting stage in this laboratory. I would also like to recognize the following individuals for their direct experimental contribution to my thesis: Dr. Ling (Lucy) Chen for the collaboration in phospho-ERK and survivin staining and discussion in pathology, Dr. Greg Lyness for the coopperation of patient tissue culture, Jianning Yang for the help with PK modeling, Tong Shen for assisting me with the suramin concentration analysis, Dr. Ling Chen and Adrianne Lovelace for the help of tissue sectioning. In addition, I want to express my gratitude to the following labmates for their friendship and help: Dr. Xiao (Shelley) Hu, Dr. Jie (Jack) Wang, Dr. Ze Lu, Bei Yu, Dan Lu, Jing Li, Jia Ji, Dr. Leijun Hu, Dr. Colin Walsh, Dr. Danny Chen, Dr. Liang Zhao, Dr. Mingjie Liu, and Dr. Zancong Shen. My appreciation also goes to Kathy Brooks, Sharon Palko, and Emily Noble for their patient help during my study. My sincere thanks also extend to my dear roommate, Xiaohui (Tracey) Wei, for her friendship and encouragements during the last few years. Thanks to all my other friends for their support during the whole training. Last but not the least, my deepest appreciation goes to my parents, my brothers and sisters-in-law. Without their endless love and support, I would not be able to go through all the way here. vi VITA September 12, 1975 ................................................ Born – Hubei, P.R. China July, 1998 ...........................................….…............ B.S., Pharmacy School of Pharmacy Beijing Medical University July, 2001 ....................................................….…... M.S., Biochemical Engineerin Tsinghua University September, 2001 – present .....………...........…...... Graduate Research Associate College of Pharmacy The Ohio State University PUBLICATIONS Papers Xin Y., Lyness G., Chen D., Song S., Wientjes M.G., and Au J. L.-S., Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C. J Urol. 2005 Jul;174(1):322-7. Xin Y., Li Q., and Cao Z.. Investigation of glutamine metabolism in hybridoma cell C50. Chinese Journal of Biotechnology, Vol. 17(4), 2001. Presentations Xin. Y., Grecula J.C., Gupta N., Wei Y., Chen L., Au J. L.-S., and Wientjes M.G., Pharmacodynamics of the chemosensitizer suramin in radiotherapy. Proceedings of the American Association for Cancer Research Annual Meeting 97, 2006. Xin Y., Chen D., Song S., Lyness G., Wientjes M.G., and Au J. L.-S., Low-dose suramin enhances antitumor activity of mitomycin C in bladder tumors. Proceedings of the American Association for Cancer Research Annual Meeting 95, 2004. vii FIELDS OF STUDY Major field: Pharmacy viii TABLE OF CONTENTS Page ABSTRACT.................................................................................................................... ii ACKNOWLEDGMENT................................................................................................. v VITA............................................................................................................................. vii LIST OF TABLES........................................................................................................ xv LIST OF FIGURES .................................................................................................... xvii Chapter 1 ........................................................................................................................... 1 BACKGROUND INFORMATION ............................................................................... 1 1.1 Introduction......................................................................................................... 1 1.2 Chemoresistance and modulation strategies ....................................................... 1 1.2.1 Chemoresistance ......................................................................................... 1 1.2.2 Growth factor signaling and resistance to cancer chemotherapy................ 4 1.2.3 Other targeted therapies to modulate chemoresistance............................... 8 1.3 Radioresistance and modulation strategies ....................................................... 10 1.3.1 Overview................................................................................................... 10 1.3.2 Combination of conventional cytotoxic agents with radiation ................. 11 ix 1.3.3 Modulating radiotherapy with molecular targeted agents ........................ 13 1.4 Modulation of hypoxia in chemo- and radiotherapy......................................... 17 1.5 Protection of normal tissue in cancer therapy................................................... 18 1.6 Suramin............................................................................................................. 19 1.7 Overview of dissertation................................................................................... 22 Chapter 2 ........................................................................................................................
Load more

Recommended publications
  • Expression of Purinergic Receptors on Microglia in the Animal Model Of
    www.nature.com/scientificreports OPEN Expression of purinergic receptors on microglia in the animal model of choroidal neovascularisation Lu Li1*, Juejun Liu1, Amin Xu1, Peter Heiduschka2, Nicole Eter2 & Changzheng Chen1 To investigate the efect of P2 receptor on microglia and its inhibitor PPADS on choroidal neovascularization. Forty CX3CR1GFP/+ mice were randomly divided into 8 groups. In addition to the normal group, the rest of groups were receiving laser treatment. The retina and choroid from the second, third, fourth and ffth group of mice were taken in the 1, 4, 7, 14 days after laser treatment. The mice in the sixth and seventh group received intravitreal injection of 2 µl PPADS or PBS respectively immediately after laser treatment. The mice in the eighth group received topical application of PPADS once per day of three days. The mice in sixth, seventh and eighth group received AF and FFA examination on the fourth day after laser treatment. Immunofuorescence histochemical staining and real-time quantitative PCR were used to evaluate P2 expression and its efect on choroidal neovascularization. After laser treatment, activated microglia can express P2 receptors (P2X4, P2X7, P2Y2 and P2Y12). The expression of P2 increased on the frst day after laser damage, peaked on the fourth day (tP2X4 = 6.05, tP2X7 = 2.95, tP2Y2 = 3.67, tP2Y12 = 5.98, all P < 0.01), and then decreased. After PPADS inhibition, compared with the PBS injection group, the mRNA of P2X4, P2X7, P2Y2 and P2Y12 were decreased signifcantly in the PPADS injection group (tP2X4 = 5.54, tP2X7 = 9.82, tP2Y2 = 3.86, tP2Y12 = 7.91, all P < 0.01) and the PPADS topical application group (tP2X4 = 3.24, tP2X7 = 5.89, tP2Y2 = 6.75, tP2Y12 = 4.97, all P < 0.01).
    [Show full text]
  • The Inflammasome Promotes Adverse Cardiac Remodeling Following Acute
    The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse Eleonora Mezzaromaa,b,c,1, Stefano Toldoa,b,1, Daniela Farkasb, Ignacio M. Seropiana,b,c, Benjamin W. Van Tassellb,c, Fadi N. Sallouma, Harsha R. Kannana,b, Angela C. Mennaa,b, Norbert F. Voelkela,b, and Antonio Abbatea,b,2 aVCU Pauley Heart Center, bVCU Victoria Johnson Center, and cSchool of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298 Edited* by Charles A. Dinarello, University of Colorado Denver, Aurora, CO, and approved October 19, 2011 (received for review May 31, 2011) Acute myocardial infarction (AMI) initiates an intense inflamma- and increased caspase-1–mediated cell death in a more severe tory response that promotes cardiac dysfunction, cell death, and model of ischemia without reperfusion. We also describe phar- ventricular remodeling. The molecular events underlying this macologic inhibition of cryopyrin and P2X7 to prevent inflam- inflammatory response, however, are incompletely understood. masome formation and ameliorate cardiac damage as a potential In experimental models of sterile inflammation, ATP released from basis for translational investigation. dying cells triggers, through activation of the purinergic P2X7 receptor, the formation of the inflammasome, a multiprotein Results complex necessary for caspase-1 activation and amplification of Caspase-1 Is Activated in AMI. Caspase-1 mRNA synthesis in- the inflammatory response. Here we describe the presence of the creased severalfold in the heart at 3 and 7 d after AMI (Fig. S1). inflammasome in the heart in an experimental mouse model of Caspase-1 activation was also increased at 7 d as measured by AMI as evidenced by increased caspase-1 activity and cytoplasmic increased procaspase-1, increased cleaved caspase-1, and in- aggregates of the three components of the inflammasome—apo- creased cleaved/procaspase-1 ratio (Fig.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • Suramin Pharmacokinetics After Regional Or Systemic
    TRANSLATIONAL RESEARCH IN CANCER: PRECLINICAL PHARMACODYNAMICS AND CANCER EPIDEMIOLOGY DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Jia Ji, M.A.S. Graduate Program in Pharmacy The Ohio State University 2009 Dissertation Committee: Dr. Jessie L.-S. Au, Advisor Dr. M. Guillaume Wientjes Dr. Dennis B. McKay Copyright by Jia Ji 2009 ABSTRACT Translational research bridges preclinical and clinical research and shortens distance between these two areas in biomedical research. In preclinical study, our laboratory has found suramin sensitization at low and non-toxic dose and antagonism at toxic dose in multiple experimental models. The first part of this dissertation, Chapter 2 and 3, aims to evaluate cellular pharmacodynamics (PD) of biphasic effect of suramin and identify potential PD endpoint for future application in clinical practice. In Chapter 2, we first established an in vitro experimental model that illustrated suramin sensitization and antagonism to cisplatin, known as DNA-damaging drug. Addition of low dose suramin enhanced cellular response to cisplatin-induced DNA damage in three aspects, which are cell cycle arrest, cell death and senescence. Chapter 3 documented that persistence of γH2AX, a marker of DNA damage, was sustained by the addition of low dose suramin compared with cisplatin-alone treatment. No significant change of γH2AX kinetics was detected when suramin biphasic effect to taxanes, non-DNA-damaging drugs, was observed under both in vitro and in vivo settings. These preclinical discoveries not only lead us to treatment-dependant mechanism of suramin sensitization effect, but also indicate prospective clinical application of γH2AX as PD endpoint in anti-cancer therapy combined with suramin.
    [Show full text]
  • Ion Channels
    UC Davis UC Davis Previously Published Works Title THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Permalink https://escholarship.org/uc/item/1442g5hg Journal British journal of pharmacology, 176 Suppl 1(S1) ISSN 0007-1188 Authors Alexander, Stephen PH Mathie, Alistair Peters, John A et al. Publication Date 2019-12-01 DOI 10.1111/bph.14749 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels Stephen PH Alexander1 , Alistair Mathie2 ,JohnAPeters3 , Emma L Veale2 , Jörg Striessnig4 , Eamonn Kelly5, Jane F Armstrong6 , Elena Faccenda6 ,SimonDHarding6 ,AdamJPawson6 , Joanna L Sharman6 , Christopher Southan6 , Jamie A Davies6 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 3Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 4Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria 5School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 6Centre for Discovery Brain Science, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.
    [Show full text]
  • Theranostics Characterization of Drug-Induced Human Mitochondrial ADP/ATP Carrier Inhibition
    Theranostics 2021, Vol. 11, Issue 11 5077 Ivyspring International Publisher Theranostics 2021; 11(11): 5077-5091. doi: 10.7150/thno.54936 Research Paper Characterization of drug-induced human mitochondrial ADP/ATP carrier inhibition Stephany Jaiquel Baron1, Martin S. King1, Edmund R.S. Kunji1, and Tom J.J. Schirris1,2 1. Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Cambridge Biomedical Campus, Keith Peters Building, Hills Road, Cambridge, CB2 0XY, United Kingdom. 2. Department of Pharmacology and Toxicology, Radboud Institute for Molecular Life Sciences, Radboud Center for Mitochondrial Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. Corresponding authors: Prof. Dr. Edmund R.S. Kunji, MRC Mitochondrial Biology Unit, University of Cambridge, Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, United Kingdom; Phone: +44 12 232 52 850; Fax: +44 12 232 52 875; Email: [email protected]; Dr. T.J.J. Schirris, ERT, Department of Pharmacology and Toxicology, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands; Phone: +31 61 517 63 47; E-mail: [email protected] © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2020.10.24; Accepted: 2021.01.18; Published: 2021.03.05 Abstract An increasing number of commonly prescribed drugs are known to interfere with mitochondrial function, causing cellular toxicity, but the underlying mechanisms are largely unknown. Although often not considered, mitochondrial transport proteins form a significant class of potential mitochondrial off-targets.
    [Show full text]
  • CHEMO/FOOD/NUTRIENT/HERB INTERACTIONS ***This List Is Most Likely Not Complete, Not 100% Accurate & Needs Constant Updating
    CHEMO/FOOD/NUTRIENT/HERB INTERACTIONS ***This list is most likely not complete, not 100% accurate & needs constant updating. DO YOUR DUE DILIGENCE, USE ONLY AS A GUIDLINE. LAST PARTIAL UPDATE 10.5.17 5-FU (5-FLUOROURACIL)—AVOID ALCOHOL (GI UPSET), BLACK COHOSH, DONG QUAI IN ESTROGEN DEPENDANT TUMORS, FOLIC ACID GREATER THAN 15 MG/D, ? BETA-CAROTENE, PROBIOTICS WHEN WBC IS <2.5. ADD—A, B6, C, E, K, PANAX GINSENG, PSK, GARLIC, GINKGO, CURCUMIN, GREEN TEA, SHITAKE MUSHROOM-LENTINAN, PROBIOTICS GLUTAMINE, AVEMAR, GINGER, FISH OIL. ABRAXANE (PACLITAXEL PROTEIN BOUND)— AVOID BLACK COHOSH, DONG QUAI IN ESTROGEN-DEPENDANT TUMORS, VALERIAN, ST. JOHNS WORT, KAVA- KAVA, GOTU KOLA (MAY ↑CNS DEPRESSION). SUBSTRATE CPY2CA, 2C9, 3A4; INDUCER CYP3A4 (WEAK), ECHINACEA. ADD—B6, GLA [EPO OR CURRANT], FISH OIL, PANAX GINSENG, GREEN TEA, RESVERATROL. ACNU NIMUSTINE) Phase 2 StUdy—USED IN GERMANY ALTRETAMINE—HEXALEN (HMM)—NO KNOWN INTERACTIONS AMRUBICIN-HYDROCHLORIDE (CALSED) (FOREIGN NAME)— BENDAMUSTINE (TREANDA)—NONE AT THIS TIME BLEOMYCIN (BLENOXANE)—NONE KNOWN. CABAZITAXEL—(JEVTANA)—AVOID GRAPEFRUIT, CYP3A METABOLIZE. CAPECITABINE (XELODA)—FOOD ↓’S ABSORPTION, ? AND ECHINACEA. CARBOPLATIN (PARAPLATIN)— AVOID BLACK COHOSH, DONG QUAI IN ESTROGEN-DEPENDANT TUMORS, NAC, L-GLUTATHIONE, ?? SILYMARIN USE WITH CAUTION. ADD—C, D, E, K, SILYMARIN, POLYSACCHARIDES [MUSHROOMS AGARICUS BLAZEI (ROYAL SUN FROM BRAZIL), ALA, GINGER, ASTRAGALUS, SPLEEN PEPTIDES (DESICCATED)], CARMUSTINE (BCNU)—NONE KNOWN. CISPLATIN (PLATINOL)—AVOID BLACK COHOSH, DONG QUAI IN ESTROGEN-DEPENDANT TUMORS, NAC, B6 300 MG/D, GINKGO + REGULAR ASPIRIN, SILYMARIN CAUTION. ADD—A, E, K, B6 <300MG/D, MELATONIN, MAGNESIUM, L-CARNITINE, GINGKO, ASTRAGALUS, PSK, SILYMARIN, GINGER QUERCETIN, SPLEEN PEPTIDES [DESICCATED]. CHLORAMBUCIL (LEUKERAN)—NONE KNOWN, ABSORPTION IS DECREASED WITH FOOD CLADRIBINE (LEUSTATIN)— AVOID ALCOHOL GI UPSET.
    [Show full text]
  • Suramin Sodium Salt
    Suramin sodium salt Product Number S 2671 Store at room temperature Product Description Precautions and Disclaimer Molecular Formula: C51H34N6Na6O23S6 For Laboratory Use Only. Not for drug, household or Molecular Weight: 1429 other uses. CAS Number: 129-46-4 Preparation Instructions Suramin inhibits parasite and human enzymes The product is soluble in water (50 mg/ml), yielding a including trypanosoma glycolytic enzymes, human clear, faint yellow solution. It is also soluble in DNA and RNA polymerases, human reverse physiological saline, sparingly soluble in 95% ethanol, transcripase, ATPase, protein kinase C, and human insoluble in benzene, ether, petroleum ether, and 3 lysosomal enzymes such as β-glucuronidase. chloroform. Suramin is a trypanocide used in the treatment of the early stages of African trypanosomiasis and is Storage/Stability effective as an anthelmintic in the treatment of Solutions deteriorate on storage and should be used onchocerciasis.1 It has been shown to have activity immediately after preparation. Protect product from against HIV, but with disappointing results and has light. been reported to have some antineoplastic activity.2 In in vitro studies, suramin inhibited the reverse References transcriptase of HIV,2,3,4 HIV infectivity, and the 1. Martindale The Extra Pharmacopoeia, 30th ed., cytopathic effect on helper/inducer T cells.5 Reynolds, J. E. F., ed., The Pharmaceutical Press (London, England: 1993), p. 528. Suramin is a hexasulfonated naphthylurea compound 2. Stein, C. A., et al., Suramin: an Anticancer Drug used as an anti-tumor drug and is a potent inhibitor of with a Unique Mechanism of Action. J. Clin. human neutrophil elastase, cathepsin G, and Oncol.,7(4), 499-508 (1989).
    [Show full text]
  • World Health Organization Model List of Essential Medicines, 21St List, 2019
    World Health Organizatio n Model List of Essential Medicines 21st List 2019 World Health Organizatio n Model List of Essential Medicines 21st List 2019 WHO/MVP/EMP/IAU/2019.06 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
    [Show full text]
  • Exatecan Mesylate), a Hexacyclic Camptothecin, on a Daily-Times- Five Schedule in Patients with Advanced Leukemia1
    2134 Vol. 8, 2134–2141, July 2002 Clinical Cancer Research Phase I and Pharmacokinetic Study of DX-8951f (Exatecan Mesylate), a Hexacyclic Camptothecin, on a Daily-Times- Five Schedule in Patients with Advanced Leukemia1 Francis J. Giles,2 Jorge E. Cortes, Conclusions: Phase II studies are warranted to further Deborah A. Thomas, Guillermo Garcia-Manero, define the activity of DX-8951f in patients with hematolog- ical malignancies. Stephan Faderl, Sima Jeha, Robert L. De Jager, and Hagop M. Kantarjian INTRODUCTION Department of Leukemia, The University of Texas M. D. Anderson Novel agents are required to improve the prognosis of Cancer Center, Houston, 77030 Texas [F. J. G.], and Daiichi patients with hematological malignancies. Camptothecin, an Pharmaceutical Corporation, Montvale, New Jersey 07645 alkaloid isolated from the Chinese tree Camptotheca acuminata, has a cytotoxic effect mediated through interference with the ABSTRACT catalytic cycle of DNA topo I3 enzyme and stabilization of the Purpose: DX-8951f is a novel hexacyclic camptothecin- covalent DNA-enzyme complex by inhibiting DNA religation analogue topoisomerase I inhibitor with both in vitro anti- (1–4). The reversible drug-enzyme-DNA ternary complex causes arrest of the replication fork and formation of single- leukemic activity and myelosuppression as a dose-limiting strand DNA breaks during DNA synthesis (5). Initial clinical toxicity in solid tumor Phase I studies. DX-8951f is active in studies of camptothecin were halted because of severe and a human acute myeloid leukemia (AML) severe combined unpredictable adverse effects (6, 7). Camptothecin derivatives, immunodeficient mouse model. In a leukemia Phase I study, including irinotecan (CPT-11) and topotecan, were developed to we investigated the toxicity profile and pharmacokinetics of improve the toxicity profile and poor aqueous solubility of the DX-8951f in patients with primary refractory or relapsed parent drug (8, 9).
    [Show full text]
  • WO 2017/123633 Al 20 July 2017 (20.07.2017) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization Illl ll II 11III I II I ill llll II III II I II International Bureau (10) International Publication Number (43) International Publication Date WO 2017/123633 Al 20 July 2017 (20.07.2017) W P O P C T (51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, C07K 14/705 (2006.01) A61K 31/00 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, CO 37/10 (2006.01) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (21) International Application Number: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, PCT/US2017/013015 RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (22) International Filing Date: TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, 11 January 2017 ( 11.01 .2017) ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (30) Priority Data: TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/277,422 11 January 2016 ( 11.01.2016) U S TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant: DIGNITY HEALTH [US/US]; 3033 N .
    [Show full text]
  • Antidepressant-Like Effects of P2 Purinergic Antagonist PPADS Is Dependent on Serotonergic and Noradrenergic Integrity
    bioRxiv preprint doi: https://doi.org/10.1101/086983; this version posted November 10, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Title: Antidepressant-like effects of P2 purinergic antagonist PPADS is dependent on serotonergic and noradrenergic integrity. Authors: Cassiano R. A. F. Diniza, Murilo Rodriguesb, Plínio C. Casarottoc, Vítor S. Pereirad, Carlos C. Crestanie, Sâmia R.L. Jocab,d*. aSchool of Medicine, Campus USP, Ribeirão Preto, SP 14049-900, Brazil bDepartment of Physics and Chemistry, School of Pharmaceutical Sciences, Campus USP, Ribeirão Preto, SP 14040-904, Brazil. cNeuroscience Center, University of Helsinki, Finland dDepartment of Clinical Medicine - Translational Neuropsychiatry Unit, Aarhus University, Denmark eLaboratory of Pharmacology, School of Pharmaceutical Sciences, UNESP - Universidade Estadual Paulista, Araraquara, SP, Brazil *Corresponding Author: Sâmia Joca. Department of Physics and Chemistry - School of Pharmaceutical Sciences of Ribeirão Preto (FCFRP) University of São Paulo (USP). AvCafe, s/n, 14040-903, Ribeirão Preto - SP, Brazil. Phone: +55-16-33154705 -Fax: +55-16-33154880. e-mail: [email protected] Samia R. L. Joca: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/086983; this version posted November 10, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.
    [Show full text]